金陵药业(000919) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥693,016,544.54, a decrease of 1.22% compared to ¥701,603,298.78 in the same period last year[3] - Net profit attributable to shareholders increased by 12.12% to ¥39,240,141.55 from ¥34,999,569.83 year-on-year[3] - Net profit for the current period is ¥44,443,693.56, an increase of 4.4% compared to ¥42,567,636.65 in the previous period[21] - Operating profit for the current period is ¥54,849,544.06, slightly down from ¥56,428,216.74, a decrease of 2.8%[21] - Basic earnings per share increased to ¥0.0769 from ¥0.0694, reflecting a growth of 7.2%[22] Cash Flow - The net cash flow from operating activities decreased significantly by 451.37%, resulting in a negative cash flow of ¥72,458,661.05 compared to a positive cash flow of ¥20,621,729.67 in the previous year[3] - Cash flow from operating activities shows a net outflow of ¥72,458,661.05, compared to a net inflow of ¥20,621,729.67 in the previous period[25] - Cash flow from investment activities resulted in a net outflow of ¥460,424,469.27, worsening from a net outflow of ¥269,446,173.11 in the previous period[25] - The net cash flow from financing activities was 8,534,333.34, compared to a negative cash flow of -67,000.00 in the previous year[26] - The total cash inflow from financing activities was ¥23,616,000.00, with no previous inflow recorded[25] - The total cash and cash equivalents at the end of the period decreased to 957,243,394.73 from 1,049,446,008.63 year-over-year[26] - The net increase in cash and cash equivalents was -524,349,156.37, compared to -248,891,096.60 in the same period last year[26] - The cash flow out from financing activities totaled 15,081,666.66, compared to 67,000.00 in the previous year[26] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,440,343,153.87, a slight decrease of 0.16% from the previous year-end[3] - The company's cash and cash equivalents decreased to RMB 976,861,077.66 from RMB 1,501,760,713.59, representing a decline of approximately 34.8%[16] - Accounts receivable increased to RMB 410,485,224.32 from RMB 320,639,675.01, reflecting a growth of about 28.0%[16] - The company's inventory stood at RMB 246,328,627.03, showing a marginal increase from RMB 245,476,356.41[16] - Total liabilities decreased to RMB 837,714,206.40 from RMB 913,096,006.32, indicating a reduction of approximately 8.2%[19] - The equity attributable to shareholders of the parent company increased to RMB 2,990,585,027.16 from RMB 2,927,728,885.61, marking an increase of about 2.1%[19] Investments and Expenses - Research and development expenses rose by 37.13% compared to the same period last year, indicating increased investment in innovation[8] - Research and development expenses increased to ¥9,516,114.99, up 37% from ¥6,939,640.95 in the previous period[21] - The company's investment income decreased by 83.63% year-on-year, attributed to reduced gains from long-term equity investments[9] - The company's prepayments increased by 136.84% compared to the beginning of the year, reflecting a rise in procurement activities[7] - The company's intangible assets increased by 81.21% compared to the beginning of the year, mainly due to the acquisition of land use rights[7] - The company completed the registration of its 2021 restricted stock incentive plan, increasing its registered capital by RMB 6,400,000 to RMB 510,400,000[13] - Jinling Pharmaceutical's subsidiary acquired land use rights for a plot in Hefei, indicating ongoing expansion efforts[13] - The company successfully completed the acquisition of a stake in Chizhou Dongsheng Pharmaceutical Co., Ltd., enhancing its investment portfolio[13] - The company's intangible assets rose significantly to RMB 254,047,202.33 from RMB 140,196,138.05, reflecting an increase of approximately 81.0%[18] Other Information - The company's weighted average return on equity increased to 1.33% from 1.22% year-on-year[3] - The first quarter report was not audited[27] - The company did not pay dividends or profits to minority shareholders during the first quarter[26]